Press Releases

• 5/16/2012
  Cubist Pharmaceuticals Marks 20th Anniversary by Making Its Largest-Ever Commitment to STEM Programs
• 5/14/2012
  Cubist Announces First Scientific Presentations of Phase 2 Data for CB-5945 in the Treatment of Opioid-Induced Constipation
• 5/7/2012
  Cubist Pharmaceuticals to Present at May Investor Conference
• 4/18/2012
  Cubist Pharmaceuticals Reports First Quarter 2012 Financial Results
• 4/17/2012
  Cubist Announces Positive Results from ENTEREG® Phase 4 Study in Patients Undergoing Radical Cystectomy
• 4/2/2012
  Cubist Pharmaceuticals to Announce Q112 Financial Results on Wednesday, April 18th, 2012
• 3/16/2012
  Cubist Opens Expanded Research and Development Facility
• 3/9/2012
  Cubist Pharmaceuticals Appoints Jane Henney to Board of Directors
• 2/20/2012
  Cubist Pharmaceuticals to Present at February/March Investor Conferences
• 2/16/2012
  Cubist Pharmaceuticals Appoints Alison Lawton to Board of Directors
• 2/9/2012
  Cubist Receives CUBICIN Paragraph IV Notice Letter
• 1/19/2012
  Cubist Pharmaceuticals Reports 2011 Fourth Quarter and Full Year Financial Results
• 1/10/2012
  Cubist Pharmaceuticals and Hydra Biosciences Announce Plans to Begin Phase 1 Clinical Trial for Novel TRPA1 Modulator to Treat Acute Pain
• 1/9/2012
  Cubist Announces Full Year 2011 Total CUBICIN Net Product Revenues of $735.5 Million, Up 18% Over 2010
• 1/4/2012
  Cubist Pharmaceuticals and The New England Patriots Radio Network Honor Merrimack, New Hampshire, Science Teacher

View Press Release Archive

• 9/06/2011
  ADOLOR CORPORATION ANNOUNCES COMPLETION OF ACQUISITION OF FULL OWNERSHIP OF ENTEREG(R) (ALVIMOPAN)
• 8/10/2011
  ADOLOR CORPORATION ANNOUNCES POSITIVE RESULTS FROM PHASE 2 PROGRAM IN OIC
• 6/14/2011
  ADOLOR CORPORATION ANNOUNCES AGREEMENT TO ACQUIRE FULL OWNERSHIP OF ENTEREG (ALVIMOPAN)
• 6/06/2011
  ADOLOR CORPORATION COMPLETES ENROLLMENT IN PHASE 2 OIC PROGRAM
• 1/10/2011
  ADOLOR CORPORATION EXPANDS PHASE 2 OPIOID INDUCED CONSTIPATION PROGRAM
• 11/03/2010
  MEDICATION USE EVALUATION OF ENTEREG (ALVIMOPAN) PUBLISHED IN THE NOVEMBER EDITION OF THE ANNALS OF PHARMACOTHERAPY
• 10/19/2010
  ADOLOR CORPORATION INITIATES PHASE 2 OIC STUDY OF ADL5945
• 11/12/2009
  ADOLOR CORPORATION INITIATES CLINICAL TESTING IN OPIOID BOWEL DYSFUNCTION PROGRAM
• 9/21/2009
  ADOLOR ACQUIRES RIGHTS TO CLINICAL-STAGE PRODUCT CANDIDATE FROM ELI LILLY AND COMPANY
• 8/20/2009
  PHARMACOECONOMIC ANALYSIS OF REPORTED USE OF ENTEREG(R) (ALVIMOPAN) PUBLISHED IN AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
• 11/18/2008
  STUDY PUBLISHED IN ARCHIVES OF SURGERY DEMONSTRATED BENEFIT OF ENTEREG(R) (ALVIMOPAN) IN POSTOPERATIVE ILEUS
• 9/02/2008
  ADOLOR REGAINS RIGHTS TO ENTEREG(R) (ALVIMOPAN) FOR OBD
• 7/24/2008
  ADOLOR PROVIDES ENTEREG(R) (ALVIMOPAN) HOSPITAL REGISTRATION UPDATE
• 7/03/2008
  ADOLOR PROVIDES UPDATE ON ENTEREG(R) (ALVIMOPAN) OBD PROGRAM
• 6/09/2008
  ENTEREG(R) (ALVIMOPAN) AVAILABLE FOR THE MANAGEMENT OF POSTOPERATIVE ILEUS
• 5/20/2008
  ADOLOR AND GLAXOSMITHKLINE ANNOUNCE FDA APPROVAL OF ENTEREG(R) (ALVIMOPAN) FOR THE MANAGEMENT OF POSTOPERATIVE ILEUS (POI)
• 1/23/2008
  ADOLOR AND GLAXOSMITHKLINE REPORT FAVORABLE FDA ADVISORY COMMITTEE MEETING FOR ENTEREG(R) (ALVIMOPAN) FOR THE MANAGEMENT OF POSTOPERATIVE ILEUS IN BOWEL RESECTION
• 1/18/2008
  ADOLOR ANNOUNCES AVAILABILITY OF BRIEFING DOCUMENTS FOR JANUARY 23RD FDA ADVISORY COMMITTEE MEETING ON ENTEREG(R) (ALVIMOPAN)
• 11/28/2007
  ADOLOR AND GLAXOSMITHKLINE ANNOUNCE FDA ADVISORY COMMITTEE TO REVIEW ENTEREG(R) (ALVIMOPAN) FOR THE MANAGEMENT OF POSTOPERATIVE ILEUS (POI)
• 8/28/2007
  FDA ACCEPTS FOR REVIEW COMPLETE RESPONSE TO APPROVABLE LETTER FOR ENTEREG(R) (ALVIMOPAN) FOR POI
• 6/11/2007
  GSK AND ADOLOR UPDATE ALVIMOPAN (ENTEREG/ENTRAREG(R)) DEVELOPMENT PROGRAM
• 4/09/2007
  GSK AND ADOLOR ANNOUNCE PRELIMINARY RESULTS FROM PHASE 3 SAFETY STUDY OF ALVIMOPAN (ENTEREG/ENTRAREG(R))